Table 3.
Reasons for Treatment Failure at Test of Cure
| Reason for Treatment Failure | Daptomycin Plus Fosfomycin, No. (%) of Patients (n = 74) | Daptomycin Alone, No. (%) of Patients (n = 81) | Proportion Difference (95% CI) | P Valuea |
|---|---|---|---|---|
| Treatment failureb | 34 (45.9) | 47 (58.0) | −12.1 (−27.7 to 3.6) | .133 |
| Mortality at TOC | 18 (24.3) | 22 (27.1) | −2.8 (−16.6 to 10.9) | .687 |
| Clinical failurec | 0 (0.0) | 3 (3.7) | −3.7 (−7.8 to .4) | .247d |
| Microbiological failure | 0 (0.0) | 9 (11.1) | −11.1 (−18.0 to –4.3) | .003d |
| Any AE leading to treatment discontinuation | 13 (17.6) | 4 (4.9) | 12.6 (2.8–22.5) | .012 |
| Additional antimicrobial therapy administered before TOCe | 9 (12.1) | 19 (23.4) | −11.3 (−23.2 to .6) | .068 |
| Lack of blood cultures at TOC | 8 (10.8) | 4 (4.9) | 5.9 (−2.6 to 14.4) | .172 |
| Loss to follow-up | 1 (1.3) | 3 (3.7) | −2.4 (−7.2 to 2.5) | .622d |
Data are presented as no. (%) unless otherwise indicated.
Abbreviations: AE, adverse event; CI, confidence interval; TOC, test of cure.
aUnless otherwise specified, P value derived from χ 2 test.
bPatients might have >1 reason for treatment failure (ie, mortality at TOC, clinical or microbiological failure, any AE leading to treatment discontinuation, additional antimicrobial therapy administered before TOC, lack of blood cultures before TOC).
cLack of clinical improvement ≥3 days after the start of therapy.
dFisher exact test.
eReceipt of potentially effective nonstudy antibiotics active against methicillin-resistant Staphylococcus aureus before TOC visit.